Clinical Review · Molecular Genetics · APOE Biology
APOE ε2, ε3, and ε4: How Two Amino Acid Substitutions Produce Three Different Clinical Phenotypes
By Brian Paquette, DO, MPH
Two single-nucleotide substitutions in exon 4 of APOE generate three protein isoforms that differ in receptor affinity, lipoprotein preference, conformational stability, and susceptibility to proteolysis. This review traces each substitution from protein chemistry to the clinical numbers — and corrects three figures that circulate widely, including the retired ε4/ε4 “risk multiplier.”
The Clinical Problem
Direct-to-consumer genotyping has moved APOE out of the research setting and into the primary care and neurology clinic, where patients now arrive holding a result they obtained without counselling. The clinician is asked two questions in the same visit: what does this gene do, and what does my particular genotype mean for me? Answering the second well requires answering the first accurately, because nearly every downstream clinical claim — lipid phenotype, age of symptom onset, amyloid-related imaging abnormality risk, response to ketone-based interventions — traces back to protein chemistry.
The difficulty is that the summary figures in wide circulation are a mixture of odds ratios, lifetime risks, and relative hazards drawn from cohorts with incompatible ascertainment. They are frequently quoted interchangeably. This review separates them.
The Gene and the Protein
APOE sits within the APOE–APOC1–APOC4–APOC2 cluster at chromosome 19q13.32 (GRCh38). The mature secreted protein is a 299–amino acid, approximately 34 kDa glycoprotein translated from a 317-residue precursor bearing an 18-residue signal peptide. Its two functional domains — an amino-terminal four-helix bundle carrying the receptor-binding region (residues 136–150 in legacy numbering) and a carboxy-terminal lipid-binding domain — are joined by a protease-sensitive hinge (Huang & Mahley, Neurobiology of Disease, 2014, DOI).
Members Only
This review continues for members
The remainder of this article — the full clinical reasoning, evidence-strength tables, and complete reference list — is available to APOE4 Insights members.
- Physician-authored, evidence-calibrated clinical reviews
- Explicit about what the data do and do not support
- No industry sponsorship, no supplement affiliates
$79 a year, with a 7-day free trial and a 30-day money-back guarantee. Founding members: $59/year with code FOUNDING.
Already a member? Log in
